CStone to out-license sugemalimab and CS1003 rights to EQRx
CStone’s licencing agreement enables EQRx to develop and commercialise the two late-stage immuno-oncology drugs outside of Greater China
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Oct 20
CStone’s licencing agreement enables EQRx to develop and commercialise the two late-stage immuno-oncology drugs outside of Greater China
09 Oct 20
Takeda to make an upfront payment of $300m and up to $740m to Arrowhead as potential milestone payments
01 Oct 20
VLP Therapeutics’ Covid-19 vaccine is said to be a self-amplifying RNA vaccine that leverages lipid nanoparticle formulation, a…
22 Sep 20
Samsung Biologics will offer large-scale commercial manufacturing in its Plant 3 along with drug product to support AstraZeneca's…
21 Sep 20
The potential Covid-19 vaccine candidate leverages Sanofi’s recombinant protein-based technology and GSK’s pandemic adjuvant technology
17 Sep 20
RDIF will supply Dr. Reddy's with 100 million doses of potential Covid-19 vaccine Sputnik V, upon receiving the…
16 Sep 20
The FDA designation enables development of Jardiance to prevent hospitalisation for heart failure and minimise the risk of…
08 Sep 20
The clinical trial in Germany will evaluate the safety and efficacy of potential Covid-19 vaccine candidate BNT162b2 in…
02 Sep 20
JTX-1811 is a monoclonal antibody, designed to selectively target immunosuppressive tumor-infiltrating T regulatory (TITR) cells
26 Aug 20
As part of the agreement, Takeda and Engitix will complete validation and preclinical development of new therapeutics for…